The national multi-center registered clinical trial of the Pulse Field Ablation Therapeutic Apparatus (PFA) for atrial fibrillation therapy under local anesthesia was officially launched in April this year. As of now, all enrolled subjects have been successfully completed. The completed clinical follow-up showed that the subjects' various indicators have recovered well, and the treatment effect is significant, with no complications such as pulmonary vein stenosis, phrenic nerve injury, or atrial esophageal fistula in any of the subjects. This brings new hope for the safe and effective treatment of atrial fibrillation patients! At the same time, this product has been approved to enter the NMPA's special review process for innovative medical devices this year, greatly accelerating the process of the first domestically approved innovative medical PFA product to enter the Chinese market!